ImmuneRegen BioSciences announces IND submission for Homspera(R) for the treatment of idiopathic pulmonary fibrosis

May 28, 2009

By hammersmith

[] –  ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., is announcing today the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to begin human clinical testing of Homspera, an analog of the endogenous neurokinin Substance P. The company plans to evaluate Homspera initially as a treatment for Idiopathic Pulmonary Fibrosis, a condition for which there are no consistently effective drugs approved for human use in the U.S.

For more information click here.